Referinţe:

1. HRA Pharma Report. Women and emergency contraception in 2012. A European Survey.

2. Rezumatul Caracteristicilor Produsului ellaOne® Consultat Septembrie 2021

3. Emergency contraception. Disponibil la https://www.nhs.uk/conditions/contraception/emergency-contraception. Consultat Septembrie 2021.

4. Glasier, A. F. et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis. Lancet. 2010 Feb 13;375(9714):555-562. Erratum in: Lancet. 2014;384(9953):1504.

5. Brache, V. et al. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three
randomized trials of emergency contraception regimens. Contraception 2013; 88(5): 611-618.

European public assessment report (EPAR) pentru ellaOne. Disponibil la https://www.ema.europa.eu/en/medicines/human/EPAR/ellaone . Consultat Septembrie 2021

Rezumatul Caracteristicilor Produsului ellaOne®. Disponibil la https://www.ema.europa.eu/en/documents/product-information/ellaone-epar-product-information_ro.pdf Consultat Septembrie 2021

Rezumat EPAR (Raportul Public European de Evaluare) pentru ellaOne®. Disponibil la: https://www.ema.europa.eu/en/documents/overview/ellaone-epar-summary-public_ro.pdf . Consultat Septembrie 2021